Urticaria is more than a skin condition. For the millions living with CSU/CIndU, it means unpredictable flares, disrupted sleep, & a disease that can impact every part of daily life. That's why #UDAY2026 matters, & why we're proud to recognize it across every site. We see you.

Today is #UrticariaDay. The daily burden of CSU and CIndU is often invisible. This #UDAY2026, we're proud to stand with our urticaria community & support the call to #TakeBackControl. Swipe to hear from Celldex team members on what this day means to them & why this work matters.

We are thrilled to share that today we announced positive topline results from the Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in CSU, which met the primary and all key secondary endpoints. For more info, please see our press release here: ir.celldex.com/news-releases…

Patient stories shape our path forward in tackling unmet needs. We recently welcomed We CU advocate Kristen Willard to share her experience living with CSU. Thank you, Kristen, for your candor and for the powerful reminder of the need for new treatment options in #urticaria.

News from #EAACI2026: We presented new data supporting barzolvolimab's first-in-class, best-in-disease profile in CSU & ColdU & positive first-in-human Phase 1 results from CDX-622, further expanding our mast cell-focused pipeline. View our presentations: celldex.com/science/

We’re pleased to announce the closing of our $345M public offering. This will support the potential commercialization of barzolvolimab, if approved, for the treatment of CSU & the continued advancement of our novel antibody-based pipeline. Read more here. ir.celldex.com/news-releases…

We're pleased to announce the completion of enrollment in our global Phase 3 program of barzolvolimab in chronic spontaneous #urticaria. Enrollment completed 6 months ahead of guidance, driven by the significant need for better treatments in CSU. Details: ir.celldex.com/news-releases…

Earlier today, @AAAAI_org shared press releases highlighting noteworthy data planned for presentation at its upcoming annual meeting, including barzolvolimab. We look forward to sharing 3 presentations at #AAAAI26 in Philadelphia, February 27 - March 2. aaaai.org/about/news/news/20…

As 2025 comes to an end, we're proud of the dedication & scientific rigor that drive our work forward. We gave back in our local communities & rang in the holiday season this month. We look forward to advancing our pipeline & making a meaningful impact on patients' lives in 2026.

We're excited to initiate our global registrational Phase 3 study of barzolvolimab in #ColdU & symptomatic dermographism, designed to establish the efficacy & safety of barzolvolimab in patients who remain symptomatic despite prior treatment. More: ir.celldex.com/news-releases…

Pumpkins, pies & plenty of Dunkin' - autumn is in full swing at Celldex. Recently, we voted on a delicious spiced maple miso caramel apple pie as our contest winner, celebrated Halloween with pumpkin carving & candy, & enjoyed a surprise morning sweet treat event. Check it out!🍁

We are thrilled to welcome Teri Lawver to our leadership team as SVP & CCO. With a notable record of success across global biopharma & medtech companies, Teri's experience will be invaluable as we prepare for the potential launch of barzolvolimab. More: ir.celldex.com/news-releases…

We presented new Phase 2 data demonstrating sustained efficacy + a well tolerated safety profile over a 20 week treatment period for barzolvolimab in two of the most common forms of #CIndU, cold urticaria (ColdU) & symptomatic dermographism (SD). ir.celldex.com/news-releases… #ACAAI25

We're excited to announce positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets mast cell depletion via stem cell factor starvation and neutralization of the alarmin thymic stromal lymphopoietin (#TSLP). Details: ir.celldex.com/news-releases…

"I think even as a provider, there have been moments where I have not fully gauged how anxiety-provoking and emotionally challenging it can be to have chronic #urticaria." Clinicians answer the hard questions about working with an often misunderstood community below. #UDAY2025

In honor of #UDAY2025, we're elevating the voices of clinicians who face the challenges of #urticaria head-on alongside their patients. Listen below as Drs. Michael Cameron, Sarina Elmariah & Daniel Soteres share insight into the exasperating symptoms #CSU and #CIndU often cause.

People with chronic #urticaria live with relentless itching, swelling & sleepless nights, yet many don’t see the burden. #UDAY2025 is a chance to raise awareness & amplify community voices. The Celldex team stands with those living with #CSU & #CIndU. We see you. #urticariaday

We are pleased to share data demonstrating barzolvolimab profoundly improves #angioedema, the swelling of the deeper dermal layers of the skin and mucous membranes, at 52 weeks in the Phase 2 clinical trial in #CSU. Learn more below & here: ir.celldex.com/news-releases… #EAACI2025

We were pleased to present new data at #EAACI2025 demonstrating profound, sustained complete response & improved quality of life at 76 weeks—7 months post-dosing with barzolvolimab in #CSU. Find details & listen to the playback of our recent webcast here. ir.celldex.com/news-releases…

Thanks to the community engagement efforts of Celldex team member Jesse Hall, we recently welcomed @BristolCC biology students & their Dean of #STEM to our Fall River branch. We appreciate opportunities to introduce students to summer internships across departments at Celldex!